Do analysts rate KROS or AIFC?

Keros Therapeutics presently has a consensus target price of $20.50, indicating a potential upside of 100.00%. Given Keros Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Keros Therapeutics is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keros Therapeutics 2 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.22 ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, KROS or AIFC?

Keros Therapeutics has higher revenue and earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Keros Therapeutics $244.06M 0.83 $87.01M -$3.01 N/A ALT5 Sigma $24.84M 2.36 -$344.51M N/A N/A

Does the media prefer KROS or AIFC?

In the previous week, Keros Therapeutics had 7 more articles in the media than ALT5 Sigma. MarketBeat recorded 10 mentions for Keros Therapeutics and 3 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of 0.47 beat Keros Therapeutics' score of -0.55 indicating that ALT5 Sigma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Negative ALT5 Sigma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ACOG or AIFC?

Alpha Cognition currently has a consensus price target of $16.00, indicating a potential upside of 76.19%. Given Alpha Cognition's stronger consensus rating and higher probable upside, analysts clearly believe Alpha Cognition is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alpha Cognition 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, ACOG or AIFC?

Alpha Cognition has higher earnings, but lower revenue than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alpha Cognition $10.22M 19.34 -$20.67M -$1.35 N/A ALT5 Sigma $24.84M 2.36 -$344.51M N/A N/A

Does the media refer more to ACOG or AIFC?

In the previous week, Alpha Cognition had 3 more articles in the media than ALT5 Sigma. MarketBeat recorded 6 mentions for Alpha Cognition and 3 mentions for ALT5 Sigma. Alpha Cognition's average media sentiment score of 0.86 beat ALT5 Sigma's score of 0.47 indicating that Alpha Cognition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ALT5 Sigma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate RNA or AIFC?

Avidity Biosciences currently has a consensus target price of $67.60, indicating a potential upside of 485.79%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 1 Sell rating(s) 12 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.28 ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, RNA or AIFC?

Avidity Biosciences has higher revenue and earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avidity Biosciences $36.68M 5.38 -$322.30M -$0.97 N/A ALT5 Sigma $24.84M 2.36 -$344.51M N/A N/A

Does the media refer more to RNA or AIFC?

In the previous week, ALT5 Sigma had 1 more articles in the media than Avidity Biosciences. MarketBeat recorded 3 mentions for ALT5 Sigma and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.02 beat ALT5 Sigma's score of 0.47 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ALT5 Sigma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer AIFC or NERV?

Minerva Neurosciences has a consensus price target of $10.50, indicating a potential upside of 159.90%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Minerva Neurosciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, AIFC or NERV?

Minerva Neurosciences has lower revenue, but higher earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.84M 2.36 -$344.51M N/A N/A Minerva Neurosciences N/A N/A -$293.42M -$29.16 N/A

Does the media prefer AIFC or NERV?

In the previous week, ALT5 Sigma and ALT5 Sigma both had 3 articles in the media. Minerva Neurosciences' average media sentiment score of 1.74 beat ALT5 Sigma's score of 0.47 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALT5 Sigma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Minerva Neurosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer AIFC or GLSI?

Greenwich LifeSciences has a consensus target price of $57.00, indicating a potential upside of 297.05%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, analysts clearly believe Greenwich LifeSciences is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Greenwich LifeSciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better valuation & earnings, AIFC or GLSI?

Greenwich LifeSciences has lower revenue, but higher earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.84M 2.36 -$344.51M N/A N/A Greenwich LifeSciences N/A N/A -$19.36M -$1.57 N/A

Does the media prefer AIFC or GLSI?

In the previous week, Greenwich LifeSciences had 2 more articles in the media than ALT5 Sigma. MarketBeat recorded 5 mentions for Greenwich LifeSciences and 3 mentions for ALT5 Sigma. Greenwich LifeSciences' average media sentiment score of 1.49 beat ALT5 Sigma's score of 0.47 indicating that Greenwich LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALT5 Sigma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Greenwich LifeSciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ALT5 Sigma (AIFC) Competitors

$0.42 +0.02 (+5.96%)

As of 08/4/2026 03:57 PM Eastern

Compare

AIFC vs. KROS, ACOG, RNA, NERV, and GLSI

Should you buy ALT5 Sigma stock or one of its competitors? MarketBeat compares ALT5 Sigma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ALT5 Sigma include Keros Therapeutics (KROS), Alpha Cognition (ACOG), Avidity Biosciences (RNA), Minerva Neurosciences (NERV), and Greenwich LifeSciences (GLSI).

How does ALT5 Sigma compare to Keros Therapeutics?

Keros Therapeutics (NASDAQ:KROS) and ALT5 Sigma (NASDAQ:AIFC) are related small-cap companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are owned by institutional investors. 12.6% of Keros Therapeutics shares are owned by insiders. Comparatively, 0.2% of ALT5 Sigma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Keros Therapeutics has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

In the previous week, Keros Therapeutics had 7 more articles in the media than ALT5 Sigma. MarketBeat recorded 10 mentions for Keros Therapeutics and 3 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of 0.47 beat Keros Therapeutics' score of -0.55 indicating that ALT5 Sigma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Keros Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative
ALT5 Sigma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Keros Therapeutics presently has a consensus target price of $20.50, indicating a potential upside of 100.00%. Given Keros Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Keros Therapeutics is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Keros Therapeutics has higher revenue and earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.83	$87.01M	-$3.01	N/A
ALT5 Sigma	$24.84M	2.36	-$344.51M	N/A	N/A

Keros Therapeutics has a net margin of -256.60% compared to ALT5 Sigma's net margin of -2,483.94%. Keros Therapeutics' return on equity of -19.30% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-19.30%	-17.91%
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

Summary

Keros Therapeutics beats ALT5 Sigma on 11 of the 14 factors compared between the two stocks.

How does ALT5 Sigma compare to Alpha Cognition?

Alpha Cognition (NASDAQ:ACOG) and ALT5 Sigma (NASDAQ:AIFC) are related small-cap companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

6.3% of ALT5 Sigma shares are held by institutional investors. 8.6% of Alpha Cognition shares are held by company insiders. Comparatively, 0.2% of ALT5 Sigma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Alpha Cognition has a net margin of -232.23% compared to ALT5 Sigma's net margin of -2,483.94%. Alpha Cognition's return on equity of -58.35% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

Alpha Cognition has higher earnings, but lower revenue than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	19.34	-$20.67M	-$1.35	N/A
ALT5 Sigma	$24.84M	2.36	-$344.51M	N/A	N/A

In the previous week, Alpha Cognition had 3 more articles in the media than ALT5 Sigma. MarketBeat recorded 6 mentions for Alpha Cognition and 3 mentions for ALT5 Sigma. Alpha Cognition's average media sentiment score of 0.86 beat ALT5 Sigma's score of 0.47 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ALT5 Sigma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alpha Cognition currently has a consensus price target of $16.00, indicating a potential upside of 76.19%. Given Alpha Cognition's stronger consensus rating and higher probable upside, analysts clearly believe Alpha Cognition is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Alpha Cognition has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

Summary

Alpha Cognition beats ALT5 Sigma on 12 of the 14 factors compared between the two stocks.

How does ALT5 Sigma compare to Avidity Biosciences?

Avidity Biosciences (NASDAQ:RNA) and ALT5 Sigma (NASDAQ:AIFC) are related small-cap companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

ALT5 Sigma has a net margin of -2,483.94% compared to Avidity Biosciences' net margin of -3,650.39%. Avidity Biosciences' return on equity of -44.92% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

6.3% of ALT5 Sigma shares are owned by institutional investors. 3.8% of Avidity Biosciences shares are owned by insiders. Comparatively, 0.2% of ALT5 Sigma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Avidity Biosciences has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

Avidity Biosciences currently has a consensus target price of $67.60, indicating a potential upside of 485.79%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.28
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Avidity Biosciences has higher revenue and earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$36.68M	5.38	-$322.30M	-$0.97	N/A
ALT5 Sigma	$24.84M	2.36	-$344.51M	N/A	N/A

In the previous week, ALT5 Sigma had 1 more articles in the media than Avidity Biosciences. MarketBeat recorded 3 mentions for ALT5 Sigma and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.02 beat ALT5 Sigma's score of 0.47 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ALT5 Sigma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Avidity Biosciences beats ALT5 Sigma on 11 of the 15 factors compared between the two stocks.

How does ALT5 Sigma compare to Minerva Neurosciences?

ALT5 Sigma (NASDAQ:AIFC) and Minerva Neurosciences (NASDAQ:NERV) are related small-cap companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

ALT5 Sigma has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.1, indicating that its share price is 110% less volatile than the broader market.

Minerva Neurosciences has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Minerva Neurosciences' return on equity of 0.00% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Minerva Neurosciences	N/A	N/A	-32.63%

Minerva Neurosciences has lower revenue, but higher earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	2.36	-$344.51M	N/A	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

Minerva Neurosciences has a consensus price target of $10.50, indicating a potential upside of 159.90%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, ALT5 Sigma and ALT5 Sigma both had 3 articles in the media. Minerva Neurosciences' average media sentiment score of 1.74 beat ALT5 Sigma's score of 0.47 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALT5 Sigma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Minerva Neurosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 0.2% of ALT5 Sigma shares are held by insiders. Comparatively, 1.7% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Minerva Neurosciences beats ALT5 Sigma on 10 of the 12 factors compared between the two stocks.

How does ALT5 Sigma compare to Greenwich LifeSciences?

ALT5 Sigma (NASDAQ:AIFC) and Greenwich LifeSciences (NASDAQ:GLSI) are related small-cap companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

ALT5 Sigma has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Greenwich LifeSciences has lower revenue, but higher earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	2.36	-$344.51M	N/A	N/A
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A

Greenwich LifeSciences has a consensus target price of $57.00, indicating a potential upside of 297.05%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, analysts clearly believe Greenwich LifeSciences is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Greenwich LifeSciences had 2 more articles in the media than ALT5 Sigma. MarketBeat recorded 5 mentions for Greenwich LifeSciences and 3 mentions for ALT5 Sigma. Greenwich LifeSciences' average media sentiment score of 1.49 beat ALT5 Sigma's score of 0.47 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALT5 Sigma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Greenwich LifeSciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 0.2% of ALT5 Sigma shares are held by insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Greenwich LifeSciences has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Greenwich LifeSciences	N/A	-941.15%	-368.53%

Summary

Greenwich LifeSciences beats ALT5 Sigma on 8 of the 13 factors compared between the two stocks.

Get ALT5 Sigma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIFC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIFC vs. The Competition

Export

Metric	ALT5 Sigma	Financial Services Industry	Finance Sector	NASDAQ Exchange
Market Cap	$55.39M	$27.34B	$14.05B	$12.76B
Dividend Yield	N/A	5.79%	5.92%	10.01%
P/E Ratio	N/A	20.27	28.97	25.53
Price / Sales	2.36	389.11	474.33	94.32
Price / Cash	N/A	153.95	38.61	49.39
Price / Book	0.05	3.38	3.73	6.11
Net Income	-$344.51M	$1.09B	$1.31B	$347.58M
7 Day Performance	13.52%	2.06%	1.46%	4.91%
1 Month Performance	-30.19%	3.26%	1.29%	-2.06%
1 Year Performance	-93.76%	-9.09%	13.60%	21.03%

ALT5 Sigma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIFC ALT5 Sigma	0.3861 of 5 stars	$0.42 +6.0%	N/A	-93.8%	$55.39M	$24.84M	N/A	170
KROS Keros Therapeutics	3.0049 of 5 stars	$9.95 -1.2%	$20.40 +105.0%	-29.9%	$196.91M	$244.06M	N/A	100	News Coverage Earnings Report Analyst Forecast Gap Down
ACOG Alpha Cognition	4.2672 of 5 stars	$8.80 +4.6%	$16.00 +81.8%	+3.9%	$191.58M	$10.22M	N/A	N/A
RNA Avidity Biosciences	2.4905 of 5 stars	$11.18 -2.7%	$67.60 +504.7%	-69.1%	$191.25M	$36.68M	N/A	190	News Coverage Analyst Upgrade
NERV Minerva Neurosciences	1.8836 of 5 stars	$4.09 -4.4%	$10.50 +156.7%	+113.5%	$190.55M	N/A	N/A	9	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIFC) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ALT5 Sigma (AIFC) Competitors

AIFC vs. KROS, ACOG, RNA, NERV, and GLSI

How does ALT5 Sigma compare to Keros Therapeutics?

Summary

How does ALT5 Sigma compare to Alpha Cognition?

Summary

How does ALT5 Sigma compare to Avidity Biosciences?

Summary

How does ALT5 Sigma compare to Minerva Neurosciences?

Summary

How does ALT5 Sigma compare to Greenwich LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIFC vs. The Competition

ALT5 Sigma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ALT5 Sigma (AIFC) Competitors

AIFC vs. KROS, ACOG, RNA, NERV, and GLSI

How does ALT5 Sigma compare to Keros Therapeutics?

Do insiders and institutionals believe in KROS or AIFC?

Which has more risk & volatility, KROS or AIFC?

Does the media prefer KROS or AIFC?

Do analysts rate KROS or AIFC?

Which has better earnings & valuation, KROS or AIFC?

Is KROS or AIFC more profitable?

Summary

How does ALT5 Sigma compare to Alpha Cognition?

Do insiders & institutionals believe in ACOG or AIFC?

Is ACOG or AIFC more profitable?

Which has better valuation and earnings, ACOG or AIFC?

Does the media refer more to ACOG or AIFC?

Do analysts prefer ACOG or AIFC?

Which has more risk & volatility, ACOG or AIFC?

Summary

How does ALT5 Sigma compare to Avidity Biosciences?

Is RNA or AIFC more profitable?

Do insiders and institutionals believe in RNA or AIFC?

Which has more volatility and risk, RNA or AIFC?

Do analysts rate RNA or AIFC?

Which has higher valuation & earnings, RNA or AIFC?

Does the media refer more to RNA or AIFC?

Summary

How does ALT5 Sigma compare to Minerva Neurosciences?

Which has more volatility & risk, AIFC or NERV?

Is AIFC or NERV more profitable?

Which has stronger earnings & valuation, AIFC or NERV?

Do analysts prefer AIFC or NERV?

Does the media prefer AIFC or NERV?

Do institutionals and insiders have more ownership in AIFC or NERV?

Summary

How does ALT5 Sigma compare to Greenwich LifeSciences?

Which has more risk and volatility, AIFC or GLSI?

Which has better valuation & earnings, AIFC or GLSI?

Do analysts prefer AIFC or GLSI?

Does the media prefer AIFC or GLSI?

Do insiders and institutionals have more ownership in AIFC or GLSI?

Is AIFC or GLSI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIFC vs. The Competition

ALT5 Sigma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools